Meaning and Methodology of Fundamental Analysis (2025)

Dividend-paying stocks: return, risk, strategy

Balance sheet and income statement made clear 2025

What is a stock exchange? Operation, actors, examples

Stock Valuation 2025: A Beginner's Guide

Objective Corporation (ASX:OCL) share fundamentals, overview



Objective Corporation is an Australian software company founded in 1987, specializing in content and records management and regulatory workflow software for government and regulated industry sectors (e.g. defense institutions, military, etc.). The company is still led by founder Tony Walls today, who owns approximately 64.81% of the shares through the TBW Group holding company, one of the highest founder ownership ratios on the Aust

Objective Corporation (ASX:OCL) share fundamentals, overview



Objective Corporation is an Australian software company founded in 1987, specializing in content and records management and regulatory workflow software for government and regulated industry sectors (e.g. defense institutions, military,

Objective Corporation Stock Analysis – State Within State

What does the stock market report section contain?



The stock price has been in a steady decline ahead of the Computer Modelling Group's 2027 Q1 report, as the transformation of the mature oil company into a serial acquisition company is taking longer than expected. That's why it deserves a place in the "Reporting from the Stock Exchange" section, which is always an update on fundamental analysis. But what is it all about?



The column is a kind of compass for investors, helping them navigate

What does the stock market report section contain?



The stock price has been in a steady decline ahead of the Computer Modelling Group's 2027 Q1 report, as the transformation of the mature oil company into a serial acquisition company is taking longer than expected. That's why it deserves a place 

Computer Modeling Group 2027 Q1 - Turnarounds seldom turn?

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides a portfolio of products used in the surgery, orthopedic, cardiovascular, and vision fields distributed through wholesalers, hospitals and retailers, and used in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. This segment also offers products and enabling technologies that support joint reconstruction, trauma, spine, sports related injuries, and others, as well as open, laparoscopic, and robotic surgical procedures; instrumentation, energy devices, stapling systems, wound closure, biosurgery products, and digital and robotic technologies; breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; intraocular lenses for cataract surgery, and other products used in cataract and refractive procedures under the TECNIS brand. The company was founded in 1886 and is based in New Brunswick, New Jersey.

The trust seeks to achieve its investment objective by holding a portfolio of the common stocks that are included in the index (the "Portfolio"), with the weight of each stock in the Portfolio substantially corresponding to the weight of such stock in the index.

Johnson & Johnson (JNJ) Presents at Deutsche Bank 2026 Healthcare Summit Transcript

FDA launches pilot program that aims to speed the time to first-in-human drug trials

J&J reports phase 2b data on less-frequent lung cancer treatment

J&J/Contineum depression candidate fails in phase 2

Johnson & Johnson (JNJ) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Apollo in talks to acquire J&J’s orthopedics unit - Bloomberg

Johnson & Johnson wins CE mark as new ACUVUE contact lens nears Europe launch

Johnson & Johnson (JNJ) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript

FDA names acting heads of drug and vaccine units to permanent roles

Insider trades: Nvidia, TSMC, and Johnson & Johnson among notable names

J&J hits all-time high as UBS assumes Buy on transition to growth

Most and least shorted mid- to mega-cap healthcare stocks at the end of August

Johnson & Johnson Replaced $913 Million In Lost Sales With $2.4 Billion In New Ones - But Kept Less Than Half

J&J's Stelara granted approval for pediatric ulcerative colitis

J&J granted China nod for oral psoriasis pill developed with Protagonist

J&J wins FDA label expansion for Imaavy in wAIHA

Johnson & Johnson: Buy IMAAVY Label Expansion First And Continued CAPLYTA Sales Push

Lawmakers ask FDA to scrutinize Chinese trials amid deaths - report

Trump nominates White House adviser Overton as next FDA commissioner

Trump expected to nominate White House aide Heidi Overton as FDA commissioner

President boasts of drug savings with Most Favored Nation policy, TrumpRx

Johnson & Johnson: Quality, But It Doesn't Deserve A Mid-20s Multiple Right Now

SA Asks: What's the outlook for Big Pharma M&A?

'Most Favored Nation' drug pricing would save Medicare more than $200B: AARP

Johnson & Johnson (JNJ) Discusses FDA Authorization and Market Introduction of OTTAVA Robotic Surgical System Transcript

Most and least shorted mid- to mega-cap healthcare stocks at the end of July

July healthcare recap: Regeneron, DexCom shine as Moderna, managed-care stocks retreat

J&J granted FDA priority review for Rybrevant Faspro in head and neck cancer

Johnson & Johnson gets $2.58B option to acquire Sail in vivo CAR-T therapies push

Johnson & Johnson shares fell after six-session winning streak

Operations comments

segment-revenues

Segment Revenues ($M)

geographic-revenues

Geographic Revenues ($M)

Accounts payable

Total current assets

Cash

Short/Current long term debt

Goodwill

Intangible assets

Net tangible assets

Property, plant and equipment

Net receivables

Shareholder's equity

Total assets

Total current liabilities

Total liabilities

Balance Sheet

Capital expenditures (TTM)

Operating cash flow (TTM)

Dividends paid (TTM)

Free cash flow (TTM)

Cash flow

DGR 10 years

DGR 15 years

DGR 3 years

DGR 5 years

DGR MR

DGR TTM

EPS growth (5y forward)

EPS growth (5y)

Time since last change announced

Dividend growth

Average yield

Yield as % of max yield

Discount to avg yield

Dividend per share

Dividend yield

Payout frequency

Maximum yield

Minimum yield

Upside potential

Dividend yield - 5y

Avg time to new high

Avg drop from high

Max time to new high

Highest price drop

Date of highest drop

Current price drop from All-time high

Downside potential

CCC status

Years of growth

EPS (1y forward)

EPS (TTM)

Ex-div date

Cash Return on Invested Capital

Return on Assets

Return on Equity

Return on Invested Capital

Financial returns

Gross profit (TTM)

Net income (TTM)

Operating income (TTM)

Revenue (TTM)

Income statement

Gross margin (TTM)

Operating margin (TTM)

Profit margin (TTM)

Margins

Average

Forward

Payout ratio

FCF per share (TTM)

Current share count

Per share

Current yield distribution

Yield at 0% (Max)

Yield at 10%

Yield at 100% (Min)

Yield at 20%

Yield at 50% (Median)

Yield at 80%

Yield at 90%

Yield distribution (inverse percentile) - 5y

All-time high

1y analyst estimate

Beta

Price at close

Daily high

Daily low

Open

Daily Volume

Next earnings date

Stock chart

EV to Sales

Price to Book

Price to Sales

Valuation (Sales/Book Value)

EV to EBITDA

Trailing P/E

Price to EBITDA

Price to FCF

Price to OCF

Valuation Ratios

JNJ

Objective Corporation Stock Analysis – State Within State

Business insight

Meaning and Methodology of Fundamental Analysis (2025)

Segment Revenues ($M)

Geographic Revenues ($M)